Management of Penetrating Aortic Ulcer (PAU) of the Thoracic Aorta
All patients with PAU require immediate medical therapy with aggressive blood pressure control and pain relief, followed by a location-based and risk-stratified approach: Type A PAU mandates urgent surgery, while Type B PAU requires initial medical management with careful surveillance and intervention reserved for complicated cases or those with high-risk imaging features. 1
Initial Management - Universal for All PAU
Regardless of location, initiate aggressive medical therapy immediately 1:
- Pain control (indicates adventitial involvement and impending rupture)
- Blood pressure reduction (target systolic BP <120 mmHg, similar to acute dissection management)
- Heart rate control with beta-blockers as first-line agents
This medical regimen is a Class I, Level C recommendation and forms the foundation of all PAU management 1.
Location-Based Treatment Algorithm
Type A PAU (Ascending Aorta/Arch)
Surgery is recommended immediately (Class I, Level C) 1. Type A PAU carries a 33-75% rupture risk and high mortality when complicated by intramural hematoma 1.
Exception: In highly selected patients with prohibitive operative risk AND uncomplicated Type A PAU without high-risk imaging features, a "wait-and-see" strategy may be considered (Class IIb, Level C) 1. However, this is the exception, not the rule—most Type A PAUs require urgent surgical intervention.
Type B PAU (Descending Thoracic Aorta)
The management hinges on whether the PAU is complicated or uncomplicated:
Uncomplicated Type B PAU
- Initial medical therapy under careful surveillance (Class I, Level C) 1
- Repetitive imaging with CT, MRI, or TEE (Class I, Level C) 1
- Imaging schedule: 1 month after diagnosis, then every 6 months if stable 1
Complicated Type B PAU
TEVAR is recommended (Class I, Level C) when any of the following are present 1:
- Recurrent or refractory pain despite medical therapy
- Signs of contained rupture (periaortic hematoma, pleural effusion)
- Rapidly growing ulcer
- Expansion of associated intramural hematoma
- Intimal disruption on contrast-enhanced CT
Surgery may be considered as an alternative based on anatomy and comorbidities (Class IIb, Level C) 1.
High-Risk Imaging Features Warranting Intervention
Even in uncomplicated Type B PAU, endovascular treatment should be considered (Class IIa, Level C) when high-risk features are present 1:
- PAU width ≥13-20 mm
- PAU depth ≥10 mm
- Significant growth >5 mm/year in width or depth
- PAU associated with saccular aneurysm
- Increasing pleural effusion
- Aortic diameter at PAU site ≥42 mm 2
The 2024 ESC guidelines specifically highlight these thresholds, though earlier 2014 guidelines noted that size-related indications (>20 mm diameter, >10 mm neck) were not universally supported by all observations 3. The most recent 2024 guidelines provide clearer thresholds and should guide current practice 1.
Conservative Management Criteria
Small, isolated, asymptomatic PAUs without high-risk features may be managed conservatively (Class IIb, Level C) with regular surveillance 1. Research supports this approach, showing that 67% of patients can be initially managed conservatively, though 13% eventually require intervention at a mean of 49.75 months due to aneurysmal degeneration 4.
Endovascular vs. Open Repair
When intervention is indicated for Type B PAU:
TEVAR is the preferred approach 1, 5:
- Technical success rates: 94-100% 5
- 30-day mortality: 4.7-5% 5, 2
- Lower early mortality compared to open surgery (5% vs 21%) 2, 6
- 5-year reintervention-free survival: 80.6% 5
Open surgery carries higher early mortality (21%) but may be necessary when anatomy is unsuitable for TEVAR 6. Most patients (90%) can be treated with standard thoracic endografts; only 10% require branched/fenestrated devices 5.
Critical Pitfalls to Avoid
Do not dismiss symptoms: Pain indicates adventitial involvement and impending rupture—this is an emergency requiring urgent imaging and intervention 3, 1
Do not rely on size alone: While larger PAUs (>20 mm width, >10 mm depth) carry higher risk, symptomatic PAUs of any size require intervention 3
Do not miss concomitant intramural hematoma: This significantly increases rupture risk and may alter management strategy 1
Do not use MRI as first-line imaging: CT angiography is superior because it reveals calcification dislodgement that frequently accompanies PAU 3
Ensure adequate follow-up: Even successfully treated PAUs require lifelong surveillance due to 19% endoleak rates and potential for late complications 5
Follow-Up Protocol
After medical management 1:
- 1 month post-diagnosis
- Every 6 months if stable
- After 2 years of stability, intervals may be extended in low-risk patients
After TEVAR 1:
- 1,6, and 12 months post-operatively
- Yearly until 5 years
- Every 2 years thereafter if no abnormalities
The overall long-term mortality for PAU is approximately 30% at mean 48-month follow-up, with no significant difference between conservatively and surgically managed groups 4. However, aortic-related mortality is preventable with appropriate intervention, as research shows no aortic-related deaths in properly selected conservatively managed patients 4.